Publications for Ademi, Z
|Up a level|
Ademi, Zanfina; Pfeil, Alena M; Hancock, Elizabeth; Trueman, David; Haroun, Rola Haroun; Deschaseaux, Celine; Schwenkglenks, Matthias (2017). Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Medical Weekly:147:w14533.
Ademi, Zanfina; Sutherland, C Simone; Van Stiphout, Joris; Michaud, Jöelle; Tanackovic, Goranka; Schwenkglenks, Matthias (2017). A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. Journal of Thrombosis and Thrombolysis, 44(4):494-506.
Blank, Patricia R; Ademi, Zanfina; Lu, Xiaoyan; Szucs, Thomas D; Schwenkglenks, Matthias (2017). Herpes zoster vaccine: A health economic evaluation for Switzerland. Human Vaccines & Immunotherapeutics, 13(7):1495-1504.
Matter-Walstra, Klazien; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, Matthias (2016). Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. British Journal of Dermatology, 174(2):463.
Ademi, Zanfina; Gloy, Viktoria; Glinz, Dominik; Raatz, Heike; Van Stiphout, Joris; Bucher, Heiner C; Schwenkglenks, Matthias (2016). Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. Swiss Medical Weekly, 146:w14382.
Gutzwiller, Florian S; Pfeil, Alena M; Ademi, Zanfina; Blank, Patricia R; Braunhofer, Peter G; Szucs, Thomas D; Schwenkglenks, Matthias (2015). Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. Pharmacoeconomics, 33(12):1311-1324.
Matter-Walstra, K; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, M (2015). A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology, 173(6):1462-1470.